Cambridge Trust Co. Sells 200 Shares of Moderna, Inc. (NASDAQ:MRNA)

Cambridge Trust Co. reduced its stake in Moderna, Inc. (NASDAQ:MRNA) by 37.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 334 shares of the company’s stock after selling 200 shares during the period. Cambridge Trust Co.’s holdings in Moderna were worth $33,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. RB Capital Management LLC increased its position in Moderna by 7.5% during the 1st quarter. RB Capital Management LLC now owns 2,267 shares of the company’s stock worth $391,000 after buying an additional 158 shares during the period. Synovus Financial Corp increased its holdings in shares of Moderna by 8.0% during the first quarter. Synovus Financial Corp now owns 4,049 shares of the company’s stock worth $704,000 after purchasing an additional 300 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Moderna by 5.1% in the first quarter. Dimensional Fund Advisors LP now owns 987,478 shares of the company’s stock valued at $170,121,000 after buying an additional 47,755 shares in the last quarter. Blair William & Co. IL boosted its stake in shares of Moderna by 12.4% in the first quarter. Blair William & Co. IL now owns 15,611 shares of the company’s stock valued at $2,689,000 after buying an additional 1,724 shares during the period. Finally, Sei Investments Co. grew its position in Moderna by 41.4% during the first quarter. Sei Investments Co. now owns 58,160 shares of the company’s stock worth $10,019,000 after buying an additional 17,031 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

Shares of MRNA stock opened at $101.41 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. The business’s 50-day moving average price is $100.63 and its 200-day moving average price is $93.64. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $144.43.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping the consensus estimate of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The business had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. During the same period last year, the company earned $3.61 EPS. The firm’s revenue was down 44.9% compared to the same quarter last year. As a group, equities analysts expect that Moderna, Inc. will post -7.51 earnings per share for the current year.

Wall Street Analyst Weigh In

MRNA has been the subject of a number of recent analyst reports. Canaccord Genuity Group upped their target price on Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research report on Friday, February 23rd. HSBC reaffirmed a “reduce” rating and issued a $86.00 price target (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Royal Bank of Canada restated an “outperform” rating and issued a $125.00 target price on shares of Moderna in a research report on Thursday, March 28th. William Blair reiterated a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Finally, Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Thursday, April 11th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $126.49.

Insider Activity

In related news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $103.38, for a total value of $1,550,700.00. Following the transaction, the director now directly owns 2,056,931 shares of the company’s stock, valued at $212,645,526.78. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $103.38, for a total value of $1,550,700.00. Following the completion of the transaction, the director now directly owns 2,056,931 shares of the company’s stock, valued at approximately $212,645,526.78. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO James M. Mock sold 647 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the sale, the chief financial officer now owns 4,300 shares in the company, valued at approximately $406,651. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 109,954 shares of company stock valued at $11,533,976. Insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.